Trial · NCT02534571
To Compare a Hemostatic Powder TC-325 and Standard Treatment in the Control of Acute Upper Gastrointestinal Bleeding From Nonvariceal Causes
NCT02534571, Phase 3, Completed, Chinese University of Hong Kong
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. To Compare a Hemostatic Powder TC-325 and Standard Treatment in the Control of Acute Upper Gastrointestinal Bleeding From Nonvariceal Causes. Trials, record NCT02534571. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02534571
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- To Compare a Hemostatic Powder TC-325 and Standard Treatment in the Control of Acute Upper Gastrointestinal Bleeding From Nonvariceal Causes
- NCT number
- NCT02534571
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 224 participants, actual
- Lead sponsor
- Chinese University of Hong Kong
- Conditions
- Acute Upper Gastrointestinal Bleeding
- Interventions
- Endoscopic Application of a Hemostatic Powder TC-325, Hemo-clipping, Epinephrine, thermo-coagulation
- First posted
- 2015-08-27
- Last updated
- 2019-10-11
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | number of participants who presents and confirmed endoscopically as recurrent upper gastro-intestinal bleeding | 30 days | ( Further bleeding is defined by failure to control bleeding at index endoscopy, renewed hematemesis, fresh melena with circulatory instability after initial control of bleeding (systolic blood pressure of 90 mmHg or less or pulse rate of 110 per minute or more) and/or a drop in haemoglobin by 2 g/dl and haematocrit by 10% over 24 hours despite adequate transfusion. Further bleeding after initial endoscopic hemostasis requires documentation with immediate endoscopy which finds fresh blood and active bleeding from a previously treated upper GIB source. Patients with further bleeding after initial endoscopic control are considered to have reached an outcome endpoint. |
| Secondary | number of participants who required subsequent endoscopic treatment upon recurrent bleeding | 30 days | number of participants who required subsequent endoscopic treatment upon recurrent bleeding |
| Secondary | number of participants who required subsequent surgical treatment upon recurrent bleeding | 30 days | number of participants who required subsequent surgical treatment upon recurrent bleeding |
| Secondary | number of participants who required further blood transfusion post randomization | 30 days | number of participants who required further blood transfusion post randomization |
| Secondary | Days of hospitalization post randomization | 60 days | Days of hospitalization post randomization |
| Secondary | number of days which participant required caring in Intensive care unit post randomization | 60 days | number of days which participant required caring in Intensive care unit post randomization |
| Secondary | number of participants with adverse events as a Measure of Safety and Tolerability (related or unrelated to endoscopic treatment) | 30 days | number of participants with adverse events as a Measure of Safety and Tolerability (related or unrelated to endoscopic treatment |
| Secondary | number of participants with mortality from all causes within 30 days randomization. | 30 days | number of participants with mortality from all causes within 30 days randomization |
| Secondary | Ease of endoscopic treatment as measured by Visual Analog Scale reported by Endoscopist | 3 days | self reported VAS scale: 0 cm to 10 cm |
| Secondary | procedure time of endoscopic treatment | 3 days | procedure time of endoscopic treatment |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02534571
GET https://conductscience.org/api/trials/v1/NCT02534571/registered